Product Information Sheet for NR-51573

Pseudomonas aeruginosa, Strain MRSN 12365

Catalog No. NR-51573

This reagent is the tangible property of the U.S. Government.

Product Description:

Pseudomonas aeruginosa (P. aeruginosa), strain MRSN 12365 was isolated in 2012 from a human respiratory sample as part of a surveillance program in the United States. *P. aeruginosa*, strain MRSN 12365 was deposited as sensitive to amikacin, aztreonam, ceftazidime, cefepime, piperacillin/tazobactam and tobramycin and resistant to imipenem, levofloxacin and meropenem, with intermediate resistance to ciprofloxacin and gentamicin.

Lot: 70025043[1] **Manufacturing Date: 07JUN2019**

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology[2]	Report results	Circular, convex, entire, smooth and cream (Figure 1)
Motility (wet mount)	Report results	Motile
VITEK® 2 (GN card)	*P. aeruginosa* (≥ 89%)	*P. aeruginosa* (99%)
Antibiotic Susceptibility Profile[3]		
VITEK® (AST-GN81 Card)		
Ampicillin	Report results	Resistant (≥ 32 µg/mL)
Amoxicillin/Clavulanic Acid	Report results	Resistant (≥ 32 µg/mL)
Piperacillin/Tazobactam	Sensitive	Sensitive (8 µg/mL)
Cefazolin	Report results	Resistant (≥ 64 µg/mL)
Cefoxitin	Report results	Resistant (≥ 64 µg/mL)
Ceftazidime	Sensitive	Sensitive (2 µg/mL)
Ceftriaxone	Report results	Resistant (≥ 64 µg/mL)
Cefepime	Sensitive	Sensitive (2 µg/mL)
Meropenem	Resistant	Intermediate (4 µg/mL)[4]
Amikacin	Sensitive	Intermediate (32 µg/mL)[4]
Gentamicin	Intermediate	Intermediate (8 µg/mL)
Tobramycin	Sensitive	Sensitive (≤ 1 µg/mL)
Ciprofloxacin	Intermediate	Inconclusive[5]
Levofloxacin	Resistant	Intermediate (4 µg/mL)[4]
Tetracycline	Report results	Resistant (≥ 16 µg/mL)
Nitrofurantoin	Report results	Resistant (≥ 512 µg/mL)
Trimethoprim/sulfamethoxazole	Report results	≥ 320 µg/mL[6]
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1410 base pairs)	≥ 99% sequence identity to *P. aeruginosa*, strain MRSN 12365 (GenBank: RXWJ01000169.1)	100% sequence identity to *P. aeruginosa*, strain MRSN 12365 (GenBank: RXWJ01000169.1)
Purity (post-freeze)[7]	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability (post-freeze)[2]	Growth	Growth

[1]NR-51573 was produced by inoculation of the depositor material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.
[2]1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar
[3]Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)
[4]The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

[5]*P. aeruginosa*, strain MRSN 12365 was deposited as being intermediately resistant to ciprofloxacin. Repeated antibiotic susceptibility testing determined that for strain MRSN 12365, the ciprofloxacin MICs are 1 µg/mL and 2 µg/mL, which are interpreted as sensitive and intermediate, respectively.

[6]Trimethoprim/sulfamethoxazole MIC interpretive standards are not available for *P. aeruginosa*, however most clinical isolates are resistant to trimethoprim/sulfamethoxazole. For more information, please refer to Köhler, T., et al. "Multidrug Efflux in Intrinsic Resistance to Trimethoprim and Sulfamethoxazole in *Pseudomonas aeruginosa*." Antimicrob. Agents Chemother. 40 (1996): 2288-2290. PubMed: 9036831.

[7]Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with and without 5% CO_2 on Tryptic Soy agar.

Figure 1: Colony Morphology



/Heather Couch/
Heather Couch 05 DEC 2019
Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898